Abstract
A tumor mass is an association of normal cells and epigenetically modified cells in continuous evolution. Heterogeneous normal cell populations are forced to survive in a hostile environment in contact with cancer cells. Resident and recruited fibroblasts, and a complex infiltrate of neutrophils, macrophages, lymphocytes and mast cells work in concert with neoplastic cells to create a new, distinctive microenvironment that allows for the generation of a new interstitium and circulation (angioarchitecture). The tumor interstitium differs from normal interstitium in several ways (i.e., an elevated intracellular pH (pHi) and pressure (pi), a lowered extracellular pH (pHe), low oxygen concentrations and low glucose levels). These differences represent important characteristics that may be modulated positively or negatively by hyperthermia, photodynamic therapy and other treatment modalities. Furthermore, the tumor microcirculation creates barriers that hinder drug delivery to the tumor mass. Systemic chemotherapy often reduces tumor burden but rarely is effective in completely eliminating the tumor. This has created the need for the development of more effective cancer therapies. To this problem, a new class of drug delivery vehicles on the order of nanometer (nanocarriers, liposomes) has been developed to minimize side effects of chemotherapy and for directly targeting cancer cells. Notwithstanding their small dimensions, the distribution of these drugs is still influenced by tumor microenvironment. An overview of ways to overcome physiological barriers and exploit tumor pathogenesis for therapeutic gain is provided.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Reference
Abramsson A, Berlin O, Papayan H et al.: Analysis of mural cell recruitment to tumor vessels. Circulation. 2002;105:112–117.
Adams RH, Alitala K.: Molecular regulation of angiogenesis and lymphangiogenesis. Nature Rev Cancer. 2007;8:464–478.
Amatthew CB, DuBose DA, Sils IV et al.: Hyperthermia –Induced changes in vascular permeability of rats, a model system to examine therapeutic interventions. J Thermal Biol. 2000;25:381–386.
Armulik A, Abramsson A, Betsholtz C.: Endothelial /Pericyte Interactions. Circ Res. 2005;97:512–523.
Asby BS, Cantab MB.: pH studies in human malignant tumors. Lancet. 1996;2:312–315.
Baronzio GF, Freitas I.: Tumor microenvironment genesis and implications on cancer immune response. In “Atlas Effectors of Anti-Tumor Immunity” . ed M V. Kiselevsky. Springer Science Business 2008, pp: 25–43.
Besic E.: Physical mechanisms and methods employed in drug delivery to tumors. Acta Pharm. 2007;57:249–268.
Behrooz A, Ismail-Beigi F.: Stimulation of glucose transport by Hypoxia: signals and mechanisms. New Physiol Sci 1999;14:(6) 105–110.
Berges G, Benjamin L.: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2002;3:401–410.
Brizel DM, Scully SP, Harrelson JM et al.: Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 1996;56:5347–5350.
Campbell RB.: Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem. 2006;6:503–512.
Campbell RB.: Battling tumors with magnetic nanotherapeutics and hyperthermia: turning up the heat. Nanomed. 2007;2:649–652.
Castano AP, Mroz P, Hamblin MR.: Photodynamic therapy and anti-tumor immunity. Nat Rev Cancer. 2006;6:535–545.
Cuenca AG, Jiang H, Hochwald SN et al.: Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107:459–66.
Dang CV, Semenza GL.: Oncogenic alterations of metabolism. TIBS. 1999;24:68–72.
Shapot VS.: Biochemical aspects of tumor growth. MIR Publishers, 1980.
Dewhirst MW, Prosnitz L, Thrall D et al.: Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol. 1997;24:616–625.
Dougherty TJ, Gomer CJ, Henderson BW et al.: Photodynamic therapy. J Natl Cancer Inst. 1998;90:889–905.
Drummond DC, Meyer O, Hong K et al.: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:692–743.
Dudar TE, Jain RK.: Differential response of normal and tumor microenvironment to hyperthermia. Cancer Res. 1984;44:605–612.
Duguet E, Treguer-Delapierre M, Delville M-H.: “Nanoparticules minerale fonctionnalisèes àdes fins d‘applications biomèdicales” . In Les Nanosciences vol. 3, Lahmani M, Boisseau P, Houdy P eds, Belin Editeur 2007, Paris: pp145–184.
Durand RE.: Distribution and Activity of Antineoplastic Drugs in a Tumor Model. J Nat Cancer Inst. 1989;81:146–152.
Dvorak HF, Brown LF, Detmar M et al.: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039.
Ehdaie B.: Application of nanotechnology in cancer research: review of progress in the National Cancer Institute‘s Alliance for Nanotechnology. Int J Biol Sci. 2007;3:108–110.
Fajardo LF, Prionas SD.: Endothelial cells and hyperthermia. Int J Hyperthermia. 1994;3:347–353.
Fattal E, Vauthier C.: Drug Delivery: Nanoparticles. In Encyclopedia of Pharmaceutical Technology. John Wiley editor 2006.
Ferrara N, Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4–25.
Folkman J.: Tumor Angiogenesis : therapeutic implications. N Engl J Med. 1971;285:1182–1186.
Freitas I.: Role of hypoxia in photodynamic therapy of tumors. Tumori. 1985 Jun 30;71:251–9.
Freitas I, Baronzio GF.: Tumor hypoxia, reoxygenation and oxygenation strategies: possible role in photodynamic therapy. J Photochem Photobiol B: Biol. 1991;11:3–30.
Freitas I, Baronzio GF, Bono B, Griffini P et al.: Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. Anticancer Res. 1996;16:1491–1502.
Freitas I, Pontiggia P, Baronzio GF et al.: Perspectives for the combined use of photodynamic therapy and hyperthermia in cancer patient. In Consensus on Hyperthermia for the 1990s. Bicker H.I. editor, Plenum Press, New York, 1990: pp 511–520.
Gabizon A, Papahadjopoulos D.: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.Proc Natl Acad Sci USA. 1988 Sep;85(18):6949–6953.
Gerweck LE, Nygaard TG, Burlett M.: Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res. 1979;39:966–972.
Gerweck LE, Richards B.: Influence of pH on the thermal sensitivity of cultured human glioblastoma cells. Cancer Res. 1981;41:845–849.
Gollnick SO, Owczarczak B, Maier P.: Photodynamic therapy and anti-tumor immunity. Lasers Surg Med. 2006 Jun;38(5):509–515.
Gomer CJ, Ferrario A, Luna M et al.: Phptodynamic therapy: combined modality approaches targeting the tumor microenvironment. Laser Surg. 2006;38:516–521.
Gregoriadis G, Ryman BE.: Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases. ,Eur J Biochem. 1972;24:485–491.
Griffioen AW, Molema G.: Angiogenesis:Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:238–268.
Gullino PM.: The internal milieu of tumors. Prog Exp Tumor Res. 1966;8:1–25.
Gullino PM. Considerations on blood supply and fluid exchange in tumors. Prog Clin Biol Res. 1982;107:1–20.
Gullino PM, Clark SH, Grantham FH.: The interstitial fluid of solid tumors. Cancer Res. 1964;24:780–794.
Gullino PM, Grantham FH.: The vascular space of growing tumors. Cancer Res. 1964;24:1727–1732.
Gullino PM, Grantham FH, Smith SH et al.: Modification of the acid base status of the internal milieu of tumors. J Natl Cancer Inst. 1965;34:857–869.
Habash RW, Bansal R, Krewski D et al.: Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed Eng. 2006;34:491–542.
Harris AL.: Hypoxia-a key regulatory factor in tumor growth. Nature Rev Cancer. 2002;2:38–47.
Harrod-Kim P.: Tumor ablation with photodynamic therapy: introduction to mechanism and clinical applications. J Vas Intervent Radiol. 2006;17:1441–1448.
Heldin CH, Rubin K, Pietras K, Ostman A.: High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–813.
Henderson BW, Dougherty TJ.: How does photodynamic therapy work? Photochem Photobiol. 1992 Jan;55(1):145–157.
Henderson BW, Waldow SM, Potter WR et al.: Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. Cancer Res. 1985;45:6071–6077.
Hlatky L, Hahnfeldt P, Tsionou C et al.: Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Br J Cancer 1996;(Suppl XII):s151–s156.
Hokland SL, Horsman MR.: The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumor response to mild hyperthermia and thermoradiosensitization. Int J Hyperthermia. 2007;23:599–606.
Horsman MR.: Tissue physiology and the response to heat. Int J Hyperthermia. 2006;22:198–205.
Horsman MR, Murata R.: Combination of vascular targeting agents with thermal or radiation therapy.Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1518–1523.
Horsman MR, Siemann DW.: Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520–11539.
Iyer AK, Khaled G, Fang J, Maeda H.: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812–818.
Jain RK.: Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987 15;47: 3039–3051.
Jain RK.: Integrative pathophysiology of solid tumors: role in detection and treatment. Cancer J Sci Am. 1998;4:S48–S57.
Jain RK.: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253–266.
Jang SH, Wientjes MG, Lu D et al.: Drug delivery and transport to solid tumors. Pharmaceutical Res. 2003;20:1337–1350.
Jirtle RL.: Chemical modification of tumor blood flow. Int J Hyperthermia. 1988;4:355–371.
Johannsen M, Gneveckow U, Eckelt L et al.: Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia. 2005;21:637–647.
Jones EL, Prosnitz LR, Dewhirst MW et al.: Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res. 2004;10:4287–4293.
Jotterand F.: Nanomedecine: how it could reshape clinical practice. Nanomed. 2007;2:401–405.
Jyotsnendu G, Amlan R, Dasgupta S et al.: Investigation on Tc tuned nano particles of magnetic oxides for hyperthermia applications. Biomed Mater Eng. 2003;13:387–399.
Kabanov AV, Gendelman HE.: Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007;32:1054–1082.
Kampinga HH.: Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006;22:191–197.
Ka-Yun NG, Matsunaga TO.: Ultrasound mediated drug delivery. In “Drug Delivery:Principles and applications” Wang B, Siahaan T and Soltero RA editors, Wiley-Interscience 2005, Hoboken; pp 245–278.
Kong G, Braun RD, Dewhirst W.: Characterization of the effect of hyperthermia on nanoparticles extravasation from tumor vasculature. Cancer Res. 2001; 61:3027–3032.
Konerding MA, Miodonski AJ, Lametschwandtner A.: Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 1995;9(4):1233–1243
Konerding MA, Steinberg F, van Ackern C, Budach V, Streffer C.: Vascular patterns of tumors: scanning and transmission electron microscopic studies on human xenografts. Strahlenther Onkol. 1992;168:444–452.
Krinik NL, Sun Y, Joyner D et al.: A polymeric drug delivery system for the simultaneous delivery of drug activable by enzymes and/or light. J Biomater SCi Polym Ed. 1994;5:303–324.
Kshirsagar NA, Pandya SK, Kirodian BG.: Liposomal drug delivery system from laboratory to clinic J Postgrad Med. 2005;51 Suppl 1:S5–15
Kunz M, Ibrahim SM.: Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003,17;2: 23–36.
Li GC.: Thermal biology and physiology in clinical hyperthermia: current status and future needs. Cancer Res. 1984;44:4886s–4893s.
Lefor AT, MaKohon S, Ackerman NB.: The effects hyperthermia on vascular permeability in experimental liver metastasis. J Surg Oncol. 1985;28:297–300.
Leunig M, Goetz AE, Dellian M et al.: Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487–490.
López-Lázaro M.: HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB J. 2006;20:828–832.
Luo F, Liu X, Yan N, Li S.: Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer. 2006 27;6:26.
Lyden D, Hattori K, Dias S et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 2001;7:1194–1201.
Maeda H, Wu J, Sawa T et al.: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284.
Maekawa S, Sugimachi K, Kitamura Y et al.: Selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin. Cancer Treat Rep. 1987;71:1053–1059.
McNeil SE.: Nanotechnology for the biologist. J Leukoc Biol. 2005 Sep;78(3):585–594.
Matsuoka F, Shinkai M, Honda H et al.: Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagnetic Res Technol. 2004;2:3.
McDonald DM, Baluk P.: Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62:5381–5385.
McDonald DM, Foss AJ.: Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev. 2000;19:109–120.
Milosevic M, Fyles A, Hedley D, Pintilie M, et al.: Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001;61:6400–6405.
Minchinton AI, Tannock I.: Drug penetration in solid tumors. Nature Rev Cancer. 2006;6: 583–592.
Moghini SM, Hunter AC, Murray JC.: Long-circulating and target-specific nanoparticles: theory and practice. Pharmacol Rev. 2001;53:283–318.
Morikawa S, Baluk P, Kaidoh T et al.: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160:985–1000.
Munn LL.: Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today. 2003 May 1;8(9):396–403.
Needham D, Anyarambhatla G, Kong G et al.: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197–1201.
Needham D, Dewhirst MW.: The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev. 2001;53:285–305.
Nilsen NO.: Endothelial changes and microvascular leakage due to hyperthermia in chick embryos.Wirchows Arch B Cell Pathol Incl Mol Pathol. 1984;46:165–174.
Nishimura Y, Hiraoka M, Jo S et al.: Microangiographic and histologic analysis of the effects of hyperthermia on murine tumor vasculature. Int J Radiat Oncol Biol Phys. 1988;15:411–420.
Oleson JR, Calderwood S-K-, Coughlin CT et al.: Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol. 1988;11:368–380.
Overgaard J, Bichel P.: The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiology. 1977;123:511–514.
Papahadjopoulos D, Allen TM, Gabizon A et al.: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 1991;88:11460–11464.
Papetti M, Herman I.: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002;282:c947–c970.
Pitt WG.: Defining the role of ultrasound in drug delivery. Review article. Am J Drug Deliver. 2003;1:27–42.
Ponce AM, Vujaskovic Z, Yuan F et al.: Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia. 2006;22:205–213.
Rasch MH, Tijssen K, VanSteveninck J et al.: Synergistic interaction of photodynamic treatment with the sensitizer aluminum phthalocyanine and hyperthermia on loss of clonogenicity of CHO cells. Photochem-Photobiol. 1996;64:586–593.
Rawat M, Singh D, Saraf S et al.: Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29:1790–1798.
Reinhold HS, Endrich B.: Tumor microcirculation as a target for hyperthermia. Int J Hyperthermia 1986;2:11–137.
Ribatti D, Vacca A, Danmacco F.: The role of vascular phase in solid tumor growth: a historical review. Neoplasia. 1999;1:293–302.
Roca C, Primo L, Valdembri D et al.: Hyperthermia inhbits angiogenesis by a Plasminogen Activator Inhibitor –I dependent mechanism. Cancer Res. 2003;63:1500–1507.
Sanga S, Sinek JP, Frieboes HB et al.: Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev. Anticancer Ther. 2006;6:1361–1376.
Sarntinoranont M, Rooney F, Ferrari M.: Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng. 2003;31:327–335.
Seshadri M, Spernyak JA, Mazurchuk R et al.: Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res. 2005;11:4241–4250.
Simionescu N, Simionescu M.: The cardiovascular system. In “Cell and Tissue Biology. A textbook of Histology” . Leon Weiss Editor. Urban & Schwarzenberg Publisher, Baltimore-Munich. 1998; pp. 355–398.
Song CW.: Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res. 1984;44:4721s–4730s.
Song CW, Chelstrom LM, Sung JH.: Effects of a second heating on tumor blood flow: Radiat Res.1990;122:66–71.
Song CW, Park H, Griffin RJ.: Theoretical and experimental basis of Hyperthermia. In Thermotherapy for neoplasia, inflammation, and pain: M. Kosaka, T. Sugahara, K.L. Schmidt, E. Simon editors, Springer Verlag Tokyo 2001, pp.394–407.
Song CW, Park HJ, Lee CK, et al.: Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia. 2005;21:761–767.
Stauffer PR.: Evolving technology for thermal therapy of cancer. Int J Hyperthermia. 2005;21: 731–744.
Sundaram J, Berlyn R., Mitragotri M et al.: An Experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes. Biophys J. 2003;84:3087–3310.
Takakura N, Watanabe T, Suenobu S et al.: A role for Hematopoietic stem cells in promoting angiogenesis. Cell. 2000;102:199–209.
Thorpe PE.: Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004 Jan 15;10(2):415–427.
Trédan O, Galmarini CM, Patel K et al.: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1454.
Tozer GM, Kanthou C, Baguley BC.: Disrupting tumor blood vessels. Nat Rev Cancer. 2005;5:423–435.
Tsutsui JM, Xie F, Porter RT.: The use of microbubbles to target drug delivery. Cardiovasc Ultrasound. 2004;2:23–30.
Vaupel P.: The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9 Suppl 5:10–7.
Vaupel P, Kallinowski F.: Physiological effects of hyperthermia. Recent Res Cancer. 1987;104: 71–109.
Vaupel P, Kallinowski F, Okunieff P.: Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors, a review. Cancer Res.1989;49:6449–6465.
Verma S, Watt GM, Mai Z et al.: Strategies for enhanced photodynamic therapy effects. Photochem Photobiol. 2007;83:996–1005.
Waldow SM, Henderson BW, Dougherty TJ.: Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo. Lasers Surg Med. 1985;5(2):83–94.
Wilson BC, Patterson MS, Lilge L.: Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci. 1997;12:182–199.
Xian X, Håkansson J, Ståhlberg A, Lindblom P et al.: Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116:642–651. CV.
Yatvin MB, Tegmo-Larsson IM, Dennis WH.: Temperature- and pH-sensitive liposomes for drug targeting. Methods Enzymol. 1987;149:77–87.
Younes M, Lechago LV, Somano JR et al.: Wide expression of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res. 1996;56:1164–1167.
Zeisser-Labouèbe M, Lange N, Gurny R et al.: Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm. 2006 Dec 1;326(1–2):174–181.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Baronzio, G., Baronzio, A., Crespi, E., Freitas, I. (2009). Effects of Tumor Microenvironment on Hyperthermia, Photodynamic and Nanotherapy. In: Baronzio, G., Fiorentini, G., Cogle, C.R. (eds) Cancer Microenvironment and Therapeutic Implications. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9576-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-4020-9576-4_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-9575-7
Online ISBN: 978-1-4020-9576-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)